Emerging biomarkers in prostate cancer

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Biomarkers may be proteins, RNA, DNA, autoantibodies or molecules that reliably diagnose cancer or serve as markers of prognosis. Prognosis is particularly important in prostate cancer, a disease many 'die with', but which kills only a minority of affected men. Prostate-specific antigen is widely used in screening for prostate cancer and has a significant false-positive rate, which leads to unnecessary biopsies, cost and anxiety. There is also a notable false-negative rate for prostate-specific antigen, with a significant number of high-grade tumors identified in men with a 'normal' prostate-specific antigen. Discovery and validation of improved diagnostic biomarkers is necessary. Biomarkers that would distinguish aggressive from more indolent forms of prostate cancer may be even more urgently required. High-throughput technologies that assay proteins, metabolites, DNA and RNA are generating candidate markers.

Original languageEnglish (US)
Pages (from-to)579-588
Number of pages10
JournalAging Health
Issue number4
StatePublished - Aug 2006


  • Biomarkers
  • Prostate cancer diagnosis
  • Prostate cancer prognosis
  • Screening

ASJC Scopus subject areas

  • Geriatrics and Gerontology


Dive into the research topics of 'Emerging biomarkers in prostate cancer'. Together they form a unique fingerprint.

Cite this